Back to Journals

Pragmatic and Observational Research

Professor Price

Observational and Pragmatic Research Institute, Observational and Pragmatic Research Institute, Singapore

Professor Price

David Price completed his medical degree at Cambridge University in 1984 and his general practitioner training in Norwich in 1989. Between 1990 and 2000, he worked as a principal in general practice in Norwich, and he continues to work there as a GP with a special interest in respiratory disease. David Price is currently the Primary Care Respiratory Society Professor of Primary Care Respiratory Medicine at the University of Aberdeen, Scotland. He is the founder and managing director of Research in Real Life in UK, and founder and director of Optimum Patient Care in UK and Observational & Pragmatic Research Institute in Singapore.

David Price is extensively involved in respiratory and allergy education and research. His areas of interest are ‘real-life’ effectiveness and cost-effectiveness of interventions, clinical trial design, compliance, and patient attitudes to their disease. He has authored over 300 peer-reviewed publications since 2000 and is responsible for approximately US$20 million in research and clinical development grants. David Price founded the Respiratory Effectiveness Group (, a not-for-profit, investigator-led initiative, which uses an international collaborative approach to explore the role of real-life research in informing clinical guidelines and improving patient care.

Editorial Board

Mario Gonzalez de la Parra, Scientific Director, Biokinetics, S.A. de C.V, Mexico City, Mexico.

John Haughney, Associate Director, Clinical R&D, NHS Greater Glasgow and Clyde, Glasgow UK; Senior Research fellow, University of Aberdeen, Aberdeen UK

Sabzali Javadov, Professor, Department of Physiology, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, USA.

Amanda Lee, Director of Institute of Applied Health Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, Scotland, UK.

Kyu Lim, Professor, Department of Biochemistry, College of Medicine, Cancer Research Institute, Infection Signaling Network Research Center, Chungnam National University, Korea.

Christoph R. Meier, Professor, Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Switzerland

Arshag D. Mooradian, Professor of Medicine, Chairman, Department of Medicine, University of Florida, Jacksonville, Florida, USA.

Aron D. Mosnaim, Professor, Department of Cellular and Molecular Pharmacology and of Psychiatry and Behavioral Sciences, Chicago Medical School at Rosalind University of Medicine and Science, North Chicago, Illinois, USA; Honorary Professor, College of Pharmacy at the University of Chile, Santiago, Chile

Emilio Perucca, Professor of Pharmacology, University of Pavia, Director of the Clinical Trial Centre at the Institute of Neurology IRCCS C. Mondino Foundation, Pavia, Italy.

Dr Job FM van Boven, Assistant Professor of Health Economics & Real-World (drug) Outcomes, Department of Clinical Pharmacy & Pharmacology, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Centre Groningen, University of Groningen, The Netherlands.

T. van der Molen, Professor, Department of General Practice, University of Groningen, The Netherlands